White Papers
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Key Takeaways from the 2023 NRDL Update
Continued importance of the NRDL
Accelerated access for innovative drugs
Evolving NRDL policy and payer landscape
Complete the form below to access the full white paper
By submitting this form, creating…
Read Now
Blog
Published September 25, 2024
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).
PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the disease progresses, it can lead to severe complications that may become life-threatening. PNH is listed in the first edition of China’s rare disease catalog, with…
Read Now
Blog
Published May 17, 2024
Executive Summary
The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024.
Some key features of the reform plan include:
The creation of premiums for incentivizing the early introduction of new innovative therapies in Japan
The establishment of post-listing price adjustment scheme by average foreign price for specific imported drugs at the time of price revision
The simplification of the price maintenance premium (PMP) system so…
Read Now
Webinars
Available On Demand
How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL?
As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for manufacturers aiming to achieve successful access and pricing outcomes.
In this webinar, a panel of Trinity Life Sciences’ Value, Access and Pricing experts will discuss the role of the new value-based assessment framework in NRDL payer decision-making and dive…
Watch Now
Webinars
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the impacts for pharma manufacturers.
Register for this webinar for a deeper dive into a few trends in the white paper. Join experts from our Evidence,…
Watch Now
White Papers
The pricing and market access (P&MA) landscape in China has been rapidly evolving as the country continuously attempts to balance rewarding innovation and sustainability of healthcare funding. China represents a unique and dynamic market archetype for manufacturers especially in terms of P&MA strategies.
China’s aging population (≥60 years) is estimated to exceed 400 million by 2035 driving a significant rise in government healthcare expenditure and medical insurance subsidies in the future. As such, the Chinese government has acknowledged the important…
Read Now
Webinars
Available On Demand
In Part 1 of this webinar series, The Path to Launch, we discussed various pathways and innovative programs to accelerate product launch in China. However, launching a product is only half of the battle. Ensuring optimal access to deliver the treatment to more patients is also critical for commercial success.Join Trinity Life Sciences’ APAC experts for Part 2 as they decode recent key pricing and access dynamics in the China pharmaceutical market and explore what strategies and levers are available to…
Watch Now
Webinars
Available On Demand
What are the latest pricing dynamics from the 2022 NRDL update that manufacturers should learn to succeed in China market access?
The 2022 National Reimbursement Drug List (NRDL) negotiation has recently published the list of successfully negotiated drugs and their post-negotiation prices. The results indicate an improved access environment for new and high-cost innovative therapies.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide an in-depth analysis of the 2022 NRDL and key trends from previous…
Watch Now
Webinars
Available On Demand
The pharmaceutical market in China has experienced tremendous growth over the past several decades and is becoming increasingly important. While many life sciences organizations consider China to be a ‘must win’ market, commercial success can be elusive. Despite the large patient base and recent economic and political tailwinds driving the advancement of the healthcare industry, sales for innovative drugs in China are often only a fraction of those in the U.S. The complex and rapidly evolving market dynamics require companies…
Watch Now
Blog
Published March 10, 2023
Executive summary
83 non-traditional Chinese medicines successfully entered the National Reimbursement Drug List (NRDL) for the first time. This is a >20% increase from the 2021 and 2020 NRDL updates, indicating the growing interest of both manufacturers and payers to ensure reimbursement for novel therapies in China.
The percentage of products achieving NRDL inclusion within one year of regulatory approval continues to increase steadily, from 24% in 2020 to 53% in the 2022 update, keeping up the strong momentum of…
Read Now
